The effects of aminoguanidine on renal changes in a baboon model of Type 1 diabetes

Journal of Diabetes and its Complications

Volumn 16, Issue 4, 2002, Pages 301-309

  Birrell, Alex M ^a   Heffernan, Scott J ^b   Kirwan, Paul ^c   McLennan, Sue ^b   Gillin, Adrian G ^a   Yue, Dennis K ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CENTRAL SYDNEY AREA HEALTH SERVICE   (Australia)

Author keywords

AGEs; Aminoguanidine; Diabetic nephropathy; Glycation; Primates

Indexed keywords

AMINOGUANIDINE; STREPTOMYCIN; CREATININE; ENZYME INHIBITOR; GLYCOSYLATED HEMOGLOBIN; GUANIDINE DERIVATIVE; NITRIC OXIDE SYNTHASE;

ANIMAL MODEL; ARTICLE; BABOON; BLOOD LEVEL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEUROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY INJURY; KIDNEY PLASMA FLOW; MALE; MEASUREMENT; MESANGIUM; MICROALBUMINURIA; NONHUMAN; PRIORITY JOURNAL; REDUCTION; URINALYSIS; ALBUMINURIA; ANIMAL; DIABETIC NEPHROPATHY; DISEASE MODEL; DRUG ANTAGONISM; EXPERIMENTAL DIABETES MELLITUS; GLOMERULUS FILTRATION RATE; KIDNEY; KIDNEY CIRCULATION; METABOLISM; PAPIO; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALBUMINURIA; ANIMAL; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, INSULIN-DEPENDENT; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GLOMERULAR FILTRATION RATE; GUANIDINES; HEMOGLOBIN A, GLYCOSYLATED; KIDNEY; MALE; NITRIC-OXIDE SYNTHASE; PAPIO; RENAL CIRCULATION; SUPPORT, NON-U.S. GOV'T; ANIMALS; DIABETES MELLITUS, TYPE 1; NITRIC OXIDE SYNTHASE;

EID: 0035992568     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(01)00225-2     Document Type: Article

References (40)

1. Measuring the volume density of the glomerular mesangium
2. A specific and sensitive assay for aminoguanidine: Its application to a study of the disposition of aminoguanidine in animal tissues
3. Renal response to restricted protein intake in diabetic nephropathy
4. Functional and structural abnormalities in the nerves of Type 1 diabetic baboons: Aminoguanidine treatment does not improve nerve function
5. Lilly Lecture 1993. Glycation and diabetic complications
6. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes
7. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats
8. Diabetes complication screening in 937 children and adolescents
9. Glomerular capillary morphology in normal humans
10. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus
11. Renal effects of infusion of rilmenidine and guanabenz in conscious dogs: Contribution of peripheral and central nervous system alpha 2-adrenoceptors
12. Role of oxygen in cross-linking and chemical modification of collagen by glucose
13. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications
14. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
15. Changes of extracellular matrix in a baboon (Papio hamadryas) model of insulin dependent diabetes: Studies using electron microscopy and X-ray diffraction techniques
16. A baboon (Papio hamadryas) model of insulin-dependent diabetes
17. Development of glomerular lesions in experimental long-term diabetes in the rat
18. A unique design for ease of access and movement of captive Papio hamadryas
19. Determination of membrane thickness distribution from orthogonal intercepts
20. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes
21. Group housing of hamadryas baboons: A new cage design based upon field studies of social organization
22. Advanced glycosylation end products in patients with diabetic nephropathy [see comments]
23. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia
24. Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats
25. Early phases in the development of diabetic glomerulopathy. A quantitative electron microscopic study
26. Angiotensin-converting enzyme inhibition in diabetic nephropathy
27. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease
28. The natural history and epidemiology of diabetic nephropathy. Implications for prevention and control
29. Retardation by aminoguanidine of development of albuminuria, mesangial expansion and tissue fluorescence in streptozocin-induced diabetic rat
30. Amelioration of mesangial volume and surface alterations following islet transplantation in diabetic rats
31. Diabetic glomerulopathy in man and experimental animal models
32. Quantitative glomerular morphology of the normal and diabetic baboon kidney
33. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C
34. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus [see comments]
35. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial
36. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation
37. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging
38. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications
39. Cellular events in the evolution of experimental diabetic nephropathy